Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases
Casero, R. A., & Marton, L. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2243 · Cited by 751
Neuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620
Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
Yip, C. K., Murata, K., Walz, T., Sabatini, D. M., & Kang, S. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.017 · Cited by 372
Retinoid therapy of high-risk neuroblastoma
Reynolds, C. P., Matthay, K. K., Villablanca, J. G., & Maurer, B. J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00108-3 · Cited by 330
Trk Receptor Expression and Inhibition in Neuroblastomas
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1815 · Cited by 307
Görgün, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., et al. (2010) · Blood · doi:10.1182/blood-2009-12-259523 · Cited by 274
Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 264
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Hogarty, M. D., Norris, M. D., Davis, K., Liu, X., Evageliou, N. F., Hayes, C. S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6866 · Cited by 262
Neuroblastoma: a disease requiring a multitude of imaging studies.
Kushner, B. H. (2004) · PubMed · Cited by 257
On Trk—The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology
Thiele, C. J., Li, Z., & McKee, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0651 · Cited by 238
Kushner, B. H., Kramer, K., & Cheung, N.-K. V. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4189 · Cited by 208
The biologic basis for neuroblastoma heterogeneity and risk stratification
Maris, J. M. (2005) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000150631.60571.89 · Cited by 201
Ozkaynak, M. F., Sondel, P. M., Krailo, M. D., Gan, J., Javorsky, B., Reisfeld, R. A., Matthay, K. K., Reaman, G. H., & Seeger, R. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4077 · Cited by 190
CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas
Fujita, T., Igarashi, J., Okawa, E. R., Gotoh, T., Manne, J., Kolla, V., Kim, J., Zhao, H., Pawel, B. R., London, W. B., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn176 · Cited by 188
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Van Maerken, T., Speleman, F., Vermeulen, J., Lambertz, I., De Clercq, S., De Smet, E., Yigit, N., Coppens, V., Philippé, J., De Paepe, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0792 · Cited by 159
Neuroblastoma: Therapeutic strategies for a clinical enigma
Modak, S., & Cheung, N.-K. V. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.006 · Cited by 159
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Barbieri, E., Mehta, P., Chen, Z., Zhang, L., Slack, A., Berg, S., & Shohet, J. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0305 · Cited by 144
Mechanism of fenretinide (4-HPR)-induced cell death
WU, J. M., Dipietrantonio, A. M., & Hsieh, T. C. (2001) · APOPTOSIS · doi:10.1023/a:1011342220621 · Cited by 129
MYCN oncoprotein targets and their therapeutic potential
Bell, E., Chen, L., Liu, T., Marshall, G. M., Lunec, J., & Tweddle, D. A. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.01.015 · Cited by 126
New therapeutic targets for the treatment of high‐risk neuroblastoma
Wagner, L. M., & Danks, M. K. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22094 · Cited by 117
Molecular pathogenesis of peripheral neuroblastic tumors
Janoueix‐Lerosey, I., Schleiermacher, G., & Delattre, O. (2010) · Oncogene · doi:10.1038/onc.2009.518 · Cited by 115
Moore, A. S., Blagg, J., Linardopoulos, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.15 · Cited by 96
Shusterman, S., Grupp, S. A., Barr, R. D., Carpentieri, D. F., Zhao, H., & Maris, J. M. (2001) · PubMed · Cited by 95
Ishola, T., & Chung, D. H. (2007) · Surgical Oncology · doi:10.1016/j.suronc.2007.09.005 · Cited by 93
Self-citationQiao, J., Kang, J., Ishola, T., Rychahou, P. G., Evers, B. M., & Chung, D. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711861105 · Cited by 77
Self-citationThe emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene
Kelleher, F. C., & McDermott, R. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.006 · Cited by 74
Gastrin-Releasing Peptide Is a Growth Factor for Human Neuroblastomas
Kim, S., Hu, W., Kelly, D. R., Hellmich, M. R., Evers, B. M., & Chung, D. H. (2002) · Annals of Surgery · doi:10.1097/00000658-200205000-00003 · Cited by 65
Self-citationEsiashvili, N., Anderson, C. M., & Katzenstein, H. M. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.12.001 · Cited by 58
MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells
Peaston, A. E., Gardaneh, M., Franco, A. V., Hocker, J. E., Murphy, K., Farnsworth, M. L., Catchpoole, D. R., Haber, M., Norris, M. D., Lock, R. B., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2144 · Cited by 53
Roy, N. V., Preter, K. D., Hoebeeck, J., Maerken, T. V., Pattyn, F., Mestdagh, P., Vermeulen, J., Vandesompele, J., & Speleman, F. (2009) · Genome Medicine · doi:10.1186/gm74 · Cited by 51
MDM2 as MYCN transcriptional target: Implications for neuroblastoma pathogenesis
Slack, A., Lozano, G., & Shohet, J. M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.050 · Cited by 39
Yalçın, B., Kremer, L. C. M., Caron, H. N., & van Dalen, E. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub2 · Cited by 33
London, W. B., Matthay, K. K., Ambros, P. F., Monclair, T. F., Pearson, A. D., Cohn, S. L., & Castel, V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.9518 · Cited by 2
Cited by
Nijhuis, A., Sikka, A., Yogev, O., Herendi, L., Balcells, C., Ma, Y., Poon, E., Eckold, C., Valbuena, G. N., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28907-3 · Cited by 110
Valles-Colomer, M., Manghi, P., Cumbo, F., Masetti, G., Armanini, F., Asnicar, F., Blanco-Miguez, A., Pinto, F., Punčochář, M., Garaventa, A., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2023.104917 · Cited by 14
Metadata
- Authors
- Colon, N. C., & Chung, D. H.
- Venue
- Advances in Pediatrics
- Publisher
- Elsevier BV
- Published
- 2011
- Volume
- 58
- Issue
- 1
- Pages
- 297-311
- ISSN
- 0065-3101 (ISSN-L)
- OpenAlex
- W4230225850
- Cited by
- 180
- References
- 39
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.